SHARE Magazine


2019?| 2018?| 2017


2019 SHARE Magazine
?


Index

??Message from the CEO
??Oral semaglutide filed in the US and EU
? The day I fired my doctor
? Safely in the Rainbow
? Shaped tablet key to oral delivery of insulin
? Novo Nordisk addresses affordable insulin
? Accelerating growth in Latin America
? Highlights from the first three months of 2019

?


2018 SHARE Magazine
?


Index

??Letter from the CEO, Lars Fruergaard J?rgensen
??Highlights from the first nine months of 2018
??Tresiba? revitalised with new ‘Hypos matter’?
? Novo Nordisk research centre opens in oxford
? Connected insulin pens poised for launch

?


Index

??Letter from the CEO, Lars Fruergaard J?rgensen
??Highlights from the first six months of 2018
? Oral semaglutide shows promising results
? Ozempic??heading for the European market
? Novo Nordisk focuses on treating obesity
? Red Cross and Novo Nordisk enters partnership


Index

??Letter from the CEO, Lars Fruergaard J?rgensen
? Highlights from the first three months of 2018
? Oral semaglutide shows promising results
? Ozempic??approved in the EU and Japan
? First phase 3a trial with oral semaglutide completed
? Updated Tresiba??label approved in the USA
? How Novo Nordisk’s products in Cuba

?


2017 SHARE Magazine
?


Q3 2017

SHARE Magazine UK?|?SHARE Magazine DK
?

Index

??Letter from the CEO, Lars Fruergaard J?rgensen
??Highlights from the first nine months of 2017
??Camilla Sylvest joins executive management
??SUSTAIN 7: Semaglutide compared to dulaglutide
??Victoza?
?CV label approved inin the US and the EU
??Fiasp?
?a?fast-acting insulin approved in the US
??Ambitious global goal: To prevent 100 million new cases of diabetes by 2045


Q2 2017

SHARE Magazine UK?|?SHARE Magazine DK
?

Index

??Letter from the CEO, Lars Fruergaard J?rgensen
??Highlights from the first six months of 2017
??Label update for Tresiba?
?submitted in the US
??A step closer towards a CV indication for Victoza?
? ??Phase 2 obesity data for semaglutide
??New data on Xultophy?
?
??Why Novo Nordisk is helping refugees


Q1 2017

SHARE Magazine UK?|?SHARE Magazine DK
?

Index

??Letter from the CEO, Lars Fruergaard J?rgensen
??Highlights from the first three months of 2017
??Doug Langa new head of North America Operations
??Fiasp?
?launched in Canada and EU markets
??New research centre in Oxford
??CHMP endorses Refixia?
?
??World Diabetes Foundation 15
th anniversary


Older investor materials

Investors download centre?|?Annual reports archive

?


Reporting on corporate responsibility
?

Finance & corporate governance

We want to be in business for the long run and deliver competitive financial returns for our shareholders in a responsible way.

About finance and corporate governance

?

Environmental responsibility

Reducing our environmental impact is both our corporate responsibility and a way to mitigate long-term risks.?

About our environmental responsibility

?

Access and affordability in diabetes

As the world’s biggest producer of medicines for diabetes, we stand on the frontline of the challenge of affordable and available insulin.?

All people diagnosed with diabetes should receive treatment

?

必威客户端